SCHEMBL3363802

SCHEMBL3363802

O=C1NC(=O)/C(=C\c2ccc(-c3ccc(C(=O)O)cc3)o2)S1

nearest known ligand 0.80

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 5/20 0.80
INSR P06213 3/20 0.80
CDK2 P24941 3/20 0.78
PIK3CG P48736 8/20 0.75
PIK3CA P42336 4/20 0.75
MEN1 O00255 2/20 0.69
POLB P06746 2/20 0.69
KMT2A Q03164 2/20 0.69
TTR P02766 1/20 0.69
TDP1 Q9NUW8 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
AHR P35869 1/20 0.65
HSPD1 P10809 1/20 0.60
HSPE1 P61604 1/20 0.60
GSK3A P49840 1/20 0.60
GSK3B P49841 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1064248 1.00 IGF1R (0.80) IGF1RINSRCDK2PIK3CGPIK3CA
SCHEMBL1064250 1.00 IGF1R (0.80) IGF1RINSRCDK2PIK3CGPIK3CA
SCHEMBL3363656 0.89 IGF1R (1.00) IGF1RINSRCDK2PIK3CGPIK3CA
SCHEMBL12989670 0.89 IGF1R (1.00) IGF1RINSRCDK2PIK3CGPIK3CA
SCHEMBL3363658 0.89 IGF1R (1.00) IGF1RINSRCDK2PIK3CGPIK3CA
SCHEMBL13388891 0.89 PIK3CG (0.73) IGF1RINSRCDK2PIK3CGPIK3CA
SCHEMBL21067321 0.88 CDK2 (1.00) IGF1RINSRCDK2PIK3CGPIK3CA
SCHEMBL1058310 0.86 PIK3CG (1.00) IGF1RINSRPIK3CGPIK3CAMEN1
SCHEMBL1058312 0.86 PIK3CG (1.00) IGF1RINSRPIK3CGPIK3CAMEN1
SCHEMBL3366662 0.86 PIK3CG (1.00) IGF1RINSRPIK3CGPIK3CAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed
US-20050042674-A9 Common ligand mimics: thiazolidinediones and rhodanines TRIAD THERAPEUTICS, INC. 2005-02-24 US disclosed
US-20040009526-A1 Common ligand mimics: thiazolidinediones and rhodanines YU LIN (US) 2004-01-15 US disclosed
WO-2003081209-A2 IDENTIFICATION OF LIGANDS FOR A RECEPTOR FAMILY AND RELATED METHODS TRIAD THERAPEUTICS, INC. (US) 2003-10-02 WO disclosed
US-20030180797-A1 Identification of ligands for a receptor family and related methods TRIAD THERAPEUTICS, INC. 2003-09-25 US disclosed
WO-2003072033-A2 COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES TRIAD THERAPEUTICS, INC. (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009526-A1 Common ligand mimics: thiazolidinediones and rhodanines GPR65, NR2E3, FGFR3 IGF1R 48/4885INSR 20/4885CDK2 2106/4885
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 IGF1R 522/4885INSR 1642/4885CDK2 3/4885
US-20050042674-A9 Common ligand mimics: thiazolidinediones and rhodanines GPR65, NR2E3, FGFR3 IGF1R 48/4885INSR 20/4885CDK2 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.